PMVP vs. CLSD, NVCT, ADAG, IMUX, DMAC, CLRB, ABEO, SCYX, VTGN, and FGEN
Should you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include Clearside Biomedical (CLSD), Nuvectis Pharma (NVCT), Adagene (ADAG), Immunic (IMUX), DiaMedica Therapeutics (DMAC), Cellectar Biosciences (CLRB), Abeona Therapeutics (ABEO), SCYNEXIS (SCYX), Vistagen Therapeutics (VTGN), and FibroGen (FGEN). These companies are all part of the "pharmaceutical preparations" industry.
PMV Pharmaceuticals (NASDAQ:PMVP) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.
PMV Pharmaceuticals has a net margin of 0.00% compared to Clearside Biomedical's net margin of -413.73%. Clearside Biomedical's return on equity of 0.00% beat PMV Pharmaceuticals' return on equity.
PMV Pharmaceuticals currently has a consensus target price of $5.75, suggesting a potential upside of 186.07%. Clearside Biomedical has a consensus target price of $4.50, suggesting a potential upside of 223.74%. Given Clearside Biomedical's higher probable upside, analysts plainly believe Clearside Biomedical is more favorable than PMV Pharmaceuticals.
90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Clearside Biomedical has higher revenue and earnings than PMV Pharmaceuticals. Clearside Biomedical is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Clearside Biomedical received 336 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. Likewise, 67.17% of users gave Clearside Biomedical an outperform vote while only 58.82% of users gave PMV Pharmaceuticals an outperform vote.
In the previous week, Clearside Biomedical had 3 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for Clearside Biomedical and 2 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 1.87 beat Clearside Biomedical's score of 0.75 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.
PMV Pharmaceuticals has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.35, suggesting that its share price is 135% more volatile than the S&P 500.
Summary
Clearside Biomedical beats PMV Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get PMV Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PMV Pharmaceuticals Competitors List
Related Companies and Tools
